Pharmacology and structural analysis of ligand binding to the orthosteric site of glutamate-like GluD2 receptors

Anders S. Kristensen, Kasper B. Hansen, Peter Naur, Lars Olsen, Natalie L. Kurtkaya, Shashank M. Dravid, Trine Kvist, Feng Yi, Jacob Pøhlsgaard, Rasmus P. Clausen, Michael Gajhede, Jette S. Kastrup, Stephen F. Traynelis

Affiliations:
Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322, USA: ASK, KBH, NLK, SMD, SFT.
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, DK-2100, Denmark: ASK, PN, LO, TK, JP, RPC, MG, JSK.
Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA: KBH, FY.
Running Title Page

a) Running head: Ligands modulating activity of the GluD2 lurcher mutant

b) Corresponding authors:

Dr. Stephen F. Traynelis
Department of Pharmacology
Emory University
Rollins Research Center
1510 Clifton Rd
Atlanta, GA 30322, USA
E-mail: strayne@emory.edu,
Phone: (404) 727-1375,

Dr. Jette S. Kastrup,
Department of Drug Design and Pharmacology
University of Copenhagen
Universitetsparken 2
2100 Copenhagen, Denmark
E-mail: jsk@sund.ku.dk
Phone: +45-353-36486

c) Number of text pages: 16

Number of tables: 3
Number of figures: 5
Number of references: 54

Abstract: 219 words

Introduction: 708 words

Discussion: 1240 words

Abbreviations:

7-CKA: 7-Chloro-4-oxo-1H-quinoline-2-carboxylic acid

AMPA: α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

CNS: Central nervous system

CTD: C-terminal domain

D-Ala: D-alanine

D-Ser: D-serine

GluD2-LBD: GluD2 ligand binding domain

GluD2\textsuperscript{LC}: GluD2 receptors containing the \textit{lurcher} mutation

iGluRs: Ionotropic glutamate receptors

ITC: Isothermal titration calorimetry

LBD: Ligand binding domain

LTP: Long-term potentiation

LTD: Long-term depression

NMDA: N-methyl-D-aspartate

NMDAR: NMDA receptor

PSD: Postsynaptic density

SAR: Structure-activity relationship
Abstract

The GluD2 receptor is a fundamental component of postsynaptic sites in Purkinje neurons and is required for normal cerebellar function. GluD2 and the closely related GluD1 are classified as members of the ionotropic glutamate receptor (iGluR) super-family on basis of sequence similarity, but do not bind L-glutamate. The amino acid neurotransmitter D-serine (D-Ser) is a GluD2 receptor ligand, and endogenous D-Ser signaling through GluD2 has recently been shown to regulate endocytosis of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type iGluRs during synaptic plasticity in the cerebellum such as long-term depression (LTD). Here, we investigate the pharmacology of the orthosteric binding site in GluD2 by examining the activity of analogs of D-Ser and GluN1 competitive antagonists at GluD2 receptors containing the lurcher mutation (GluD2\textsuperscript{LC}), which promotes spontaneous channel activation. We identify several compounds that modulate GluD2\textsuperscript{LC}, including a halogenated alanine analog as well as the kynurenic acid analog 7-chloro-4-oxo-1H-quinoline-2-carboxylic acid (7-chlorokynurenic acid; 7-CKA). By correlating thermodynamic and structural data for 7-CKA binding to the isolated GluD2 ligand binding domain (GluD2-LBD), we find that binding of 7-CKA to GluD2-LBD differs from D-Ser by inducing an intermediate cleft-closure of the clamshell-shaped LBD. The GluD2 ligands identified here can potentially serve as a starting point for development of GluD2-selective ligands useful as tools in studies of the signaling role of the GluD2 receptor in the brain.
Introduction

The GluD2 receptor (also known as delta2 or Gluδ2) and its closely related parologue GluD1 are classified to the ionotropic glutamate receptor (iGluR) superfamily on basis of sequence similarity to the 16 other known iGluR subunit genes (Araki et al., 1993; Lomeli et al., 1993). Like the other iGluR subtypes (i.e. the N-methyl-D-aspartate (NMDA), AMPA and kainate receptors), GluD2 receptors are predominantly localized in the postsynaptic density (PSD) of excitatory synapses in the central nervous system (CNS). GluD2 was previously designated as an ‘orphan’ iGluR as no endogenous ligands had been identified that could bind and activate the receptor (Araki et al., 1993; Lomeli et al., 1993). D-Ser and glycine have now been identified as ligands for GluD2 (Naur et al., 2007). X-ray crystal structures of the isolated GluD2 ligand binding domain (LBD) show that ligand-binding to the clamshell-shaped LBD induces a closed-cleft conformation similar to those observed for NMDA receptor (NMDAR), AMPA receptor and kainate receptor subtypes (Naur et al., 2007). Ligand-induced closure of the LBD is the initial conformational change that triggers ion channel gating in NMDA, AMPA, and kainate receptors, but ligand binding to the GluD2 LBD does not promote gating of the transmembrane ion channel when GluD2 is expressed as a homomeric tetramer. Thus, by its lack of ionotropic activity, the function of the GluD2 receptor in excitatory transmission appears to be fundamentally different from other iGluRs.

The role of GluD2 in the CNS is most studied in the cerebellum, where GluD2 receptors are expressed in glutamatergic synapses of the Purkinje-type neurons (Hirai et al., 2003; Yuzaki, 2004; Yuzaki, 2009). A key role for GluD2 in post-synaptic functions in cerebellar Purkinje neurons, including induction of cerebellar long-term depression (LTD), a form of synaptic plasticity that underlies motor learning, has been demonstrated (Hirai et al., 2003; Yuzaki, 2003).
Considerable experimental evidence exists that argue against an ionotropic synaptic signaling function of GluD2. For example, it has been demonstrated that transgenic mice carrying GluD2 mutations to abolish ion permeation of through the putative GluD2 ion channel pore have a normal phenotype and show intact cerebellar LTD (Kakegawa et al., 2007). Still, endogenous D-Ser binding to GluD2 has been shown to regulate LTD in Purkinje neurons (Kakegawa et al., 2011). This modulation required the intact intracellular C-terminal domain (CTD) of GluD2, which interacts with a range of scaffolding and signaling proteins. It can be speculated that D-Ser binding to the extracellular LBD may induce conformational changes at the CTD that potentially control GluD2 interactions with intracellular effector proteins required for LTD induction, suggesting a possible metabotropic signaling role of GluD2 conceptually akin to the recently identified metabotropic component of ligand-mediated NMDA receptor signaling in hippocampal LTD (Nabavi et al., 2013). In addition to a direct signaling role, the extracellular part of GluD2 binds the protein Cbln1, which is secreted from cerebellar granule cells, and this interaction is essential for synapse integrity between Purkinje cells and cerebellar granule cells in adult mice (Matsuda et al., 2010; Matsuda and Yuzaki, 2011; Miura et al., 2009; Yuzaki, 2010; Yuzaki, 2011). These data support the idea that GluD2 also has a structural role in synapse formation (Ito-Ishida et al., 2014).

The realization of an active signaling function of GluD2 prompts development of GluD2-selective ligands that can be used as pharmacological tools to further address the molecular function as well as the cellular mechanisms of the receptor. The lurcher mutant of GluD2 (GluD2<sup>LC</sup>) exhibit spontaneously ion channel activity in the absence of ligand binding (Wollmuth et al., 2000; Zuo et al., 1997), and a previous study identified several ligands capable of blocking the open ion channel of GluD2<sup>LC</sup> receptors (Williams et al., 2003). Although D-Ser
and glycine do not activate currents at wild-type GluD2, both ligands can inactivate spontaneous activated \( \text{GluD2}^{\text{LC}} \) receptors, showing that ligand binding to the LBD can induce conformational changes within the full-length GluD2 receptor (Hansen et al., 2009; Naur et al., 2007). In the present study, we have characterized a series of new compounds at \( \text{GluD2}^{\text{LC}} \). We identify several compounds with potency and activity similar to D-Ser at \( \text{GluD2}^{\text{LC}} \), including the kynurenic acid analog 7-CKA. Using X-ray crystallography and isothermal titration calorimetry, we establish the structural and thermodynamic basis of 7-CKA binding at the isolated GluD2 LBD.
Materials and Methods

Materials – Ligands were purchased from Tocris (Ellisville, MO), Ascent Scientific (Weston-Super-Mare, UK), Enamine (Monmouth Jct., NJ), BioNet (Cornwall, UK), InterBioScreen (Chernogolovka, Russia), Alinda Chemical (Moscow, Russia), Maybridge (Leicestershire, UK), Chembridge (San Diego, CA), Princeton BioMolecular Research (Princeton, NJ), Matrix Scientific (Columbia, SC), or Sigma (St. Louis, MO).

DNA constructs, cRNA synthesis and protein expression – Rat cDNA for GluD2 (GenBank number U08256) were provided by Dr. J. Boulter (University of California), and sub-cloned into a modified pCI-neo vector (Promega Corp., Madison, WA) as previously described (Hansen et al., 2009). cRNA were synthesized in vitro using the mMessage mMachine kit (Applied Biosystems, Austin, TX). For recombinant bacterial expression and purification of the LBD from rat GluD2, the GluD2-S1S2 construct was used as previously described (Naur et al., 2007). The concentration of protein was determined using the Bradford protein assay.

Electrophysiology – cRNA for rat GluD2 (hereafter GluD2) and GluD2^{LC} (alanine to serine mutation; GluD2-A754S) were injected into *Xenopus laevis* oocytes, as previously described (Hansen et al., 2009). Two-electrode voltage-clamp current recordings were made 48-72 hours post injection. The recording solution contained (in mM) 90 NaCl, 3 KCl, 10 HEPES, 0.5 BaCl₂; pH 7.6. Solution exchange was computer controlled through an 8-modular valve positioner (Digital MVP Valve, Hamilton Company, Reno, NV). Voltage and current electrodes were filled with 0.3 and 3.0 M KCl, respectively, and current responses recorded at a holding potential of -40 to -60 mV. Data acquisition and voltage control were accomplished with a two-electrode voltage-clamp amplifier (OC-725, Warner Instruments, Hamden, CT). During screening of compounds at GluD2^{LC}, the ligand activity was expressed as percent of the mean response to 1
mM D-Ser (~4-fold higher than D-Ser EC$_{50}$). D-Ser was applied at the beginning and end of each protocol. Test compounds were applied at either 100 µM or 1 mM, depending on the solubility and the availability of the compound. Concentration–response data were in general obtained from at least 6 oocytes from two different frogs. Concentration–response data for individual oocytes were normalized to the maximal response to D-Ser (10 mM) determined in the same recording and fitted by the Hill equation. Fitted EC$_{50}$ values, Hill slopes, and maximal relative responses (i.e. relative efficacy) from individual oocytes were used to calculate the mean and SEM.

Crystallization and structure determination – For crystallization experiments, 7-CKA was added in excess of saturation to a GluD2-LBD protein solution of 6.2 mg/ml in 20 mM HEPES (pH 7.0), 10 mM NaCl, 1 mM EDTA. This gave rise to crystal formation in the test tube within a few days. Crystals were cryoprotected by transferring 1 µl of protein solution containing crystals onto a cover slide and adding glycerol to final concentration of 30% w/v before flash-cooling in liquid nitrogen. A dataset extending to 2.5 Å resolution was obtained at 100 K at the I911-2 beamline at MAX-lab, Lund, Sweden (Table 3). The data were indexed and integrated using the diffraction data-integration program iMosflm and scaled using the program Scala in the CCP4 software package (Winn, 2003). The structure was solved by molecular replacement using the program Phaser implemented in CCP4 and the apo structure of GluD2-LBD (PDB entry 2V3T; molecule A) as search model.

Ab initio calculations on 7-CKA were performed using the B3LYP function (Becke, 1993; Lee et al., 1988) to determine geometries and energies. Two tautomeric states of 7-CKA were built and geometry optimizations were performed with the SVP basis set (Schäfer et al., 1992). The Final energies were determined with the TZVPP basis set (Weigend et al., 1998). All
calculations were performed with Turbomole 6.3 (University of Karlsruhe and Forschungszentrum Karlsruhe GmbH, 1989-2007, TURBOMOLE GmbH, since 2007; available from http://www.turbomole.com) and with continuum conductor-like screening model COSMO (Klamt and Schuurmann, 1993) with a dielectric constant of 80.

The protein structure was subjected to simulated annealing refinement followed by iterative cycles of model building in Coot (Emsley and Cowtan, 2004) and refinement in CNS (Brunger et al., 1998) and Phenix (Adams et al., 2010) until R_work/R_free converged. For refinement statistics, see Table 3. The atomic coordinates of the GluD2-LBD structure in complex with 7-CKA have been deposited in the Protein Data Bank with accession code 5CC2. Degree of domain closure was calculated using DynDom (Hayward and Berendsen, 1998).

Isothermal titration calorimetry (ITC) – ITC was carried out using a VP-ITC calorimeter from MicroCal, LLC (Northampton, MA) as previously described (Naur et al., 2007). Briefly, the calorimeter cell (1.40 ml) was filled with purified GluD2-LBD in ITC buffer (in mM: 100 HEPES, 100 NaCl, 2 KCl, pH 7.5) at 20 °C. For D-Ala, 50 injections of 20 mM ligand solutions in ITC buffer were carried out at 3-min intervals with 3 μl in the initial injection and 6 μl in the subsequent injections. β-fluoro-DL-alanine (20 mM in ITC buffer) was titrated with 20 injections of 15 μl with 3-min intervals into GluD2-LBD solution (1 mg/ml). 7-CKA (1 mM in ITC buffer) was titrated with 3-min intervals and the initial injection of 3 μl and the remaining of 10 μl into a 2.5 mg/ml solution of GluD2-LBD. The heat of dilution obtained from injecting the ligand into buffer was subtracted before the fitting process. The data analysis was performed using Origin 7.0 (MicroCal) for ITC by using a single binding-site model. The first data points in the analysis were discarded. The stoichiometry N was fixed to 1 in the fitting process.
Data analysis – Data were analyzed with the program GraphPad Prism 6.0 (GraphPad Software, San Diego, CA) and the program Clampfit (Axon Instruments, Union City, CA, USA) software. Composite concentration–response data were fitted to the Hill equation:

\[ \Delta I = \frac{\Delta I_{\text{max}}}{1 + 10^{((\log EC_{50} - \log [A]) \times n_H)}} \]

where \(\Delta I_{\text{max}}\) is the maximum current in response to the ligand, \(n_H\) denotes the Hill coefficient, \([A]\) is the ligand concentration, and \(EC_{50}\) is the ligand concentration that produces half-maximum current response. The \(EC_{50}\) and \(n_H\) from the individual oocytes were used to calculate the mean and standard error of mean (SEM). For graphical presentation, data sets from individual oocytes were normalized to the maximum current response in the same recording, making it possible to calculate the mean and the SEM for each data point. The averaged data points were then fitted to the Hill equation and plotted together with the resulting curve.
Results

Screening of compounds as GluD2 ligands – We have previously found that D-Ser, glycine, and D-Ala are capable of binding to GluD2. Although these ligands cannot initiate ion permeation in full-length wild-type GluD2 receptors expressed in heterologous systems, they can inactivate the spontaneous currents generated by GluD2 carrying the lurcher mutation (Hansen et al., 2009; Naur et al., 2007). Thus, we hypothesized that measurement of GluD2LC current can be used to detect novel ligands for the orthosteric binding site in GluD2. We assembled a library of commercially available analogs of D-Ser and other amino acids (Supplemental Table S1 to S4). The GluD2 orthosteric binding site is most similar to the glycine binding site of the NMDAR GluN1 subunit, which also binds D-Ser and glycine. Therefore, we speculated that GluN1 ligands might have affinity for GluD2 and we thus included a range of known GluN1 competitive antagonists and structural analogs hereof in the library (Supplemental Table S4). We initially screened the activity of the library compounds (91 in total) at GluD2LC receptors expressed in Xenopus oocytes using two-electrode voltage-clamp electrophysiology (Fig. 1 and Supplementary Table S1 to S4). Compound activity was defined as a change in the spontaneous activity of GluD2LC induced by compound application at concentrations of either 100 µM or 1 mM, depending on the solubility of the compound. No compounds induced an increase in the GluD2LC-mediated spontaneous current (data not shown). Nine compounds were found to inactivate GluD2LC currents by ≥50% of the inactivation produced by a similar concentration of D-Ser (Fig. 1 and Supplementary Table S1). None of these compounds were capable of producing a detectable current response at recombinant wild-type GluD2 expressed in Xenopus oocytes (N = 4-8 oocytes for each compound).
Concentration-response relationship for novel GluD2 ligands – Among the compounds identified to display the highest activity relative to D-Ser for inactivation of GluD2⁸⁷ current (Fig. 1), we selected compounds representing different chemical classes for generation of full concentration-response data at GluD2⁸⁷ to determine compound potency (i.e. EC₅₀) and relative efficacy compared to that of D-Ser (Fig. 2). The resulting fitted EC₅₀ values, Hill slopes, and relative efficacies are summarized in Table 1. None of the tested compounds displayed higher potency than D-Ser. The two most potent compounds were the D-Ser analog β-fluoro-DL-alanine and the NMDAR subunit GluN1 competitive antagonist 7-chlorokynurenic acid (7-CKA), which inactivated GluD2⁸⁷ with potencies close to that of D-Ser. EC₅₀ values for inhibition were 312 µM and 306 µM for β-fluoro-DL-alanine and 7-CKA, respectively, compared to 250 µM for D-Ser (Fig. 2 and Table 1).

Thermodynamic characterization of ligand binding to the GluD2 ligand binding domain – To further study the ligand-binding characteristics of the two most potent new ligands, 7-CKA and analog β-fluoro-DL-alanine, we performed isothermal titration calorimetry (ITC) to determine the binding affinity (Kₐ, ΔG), enthalpy (ΔH), and entropy (ΔS) of ligands for the purified GluD2-LBD (Fig. 3 and Table 2). We also included D-Ala in the ITC analysis. ITC previously has been employed to study ligand binding to isolated LBDs from the AMPA-type iGluR subunit GluA2 (Kasper et al., 2006; Martinez et al., 2014), GluA4 (Madden et al., 2000) and GluD2 (Naur et al., 2007). Interestingly, 7-CKA binds GluD2-LBD with the highest affinity among compounds characterized by ITC (10-fold higher Kₐ than D-Ser). Furthermore, 7-CKA has a thermodynamic profile that is very different compared to those of the amino acid ligands β-fluoro-DL-alanine, D-
Ser, D-Ala and glycine (Table 2). Whereas the amino acid ligands elicit a small positive change in enthalpy and thus their binding is purely entropy-driven, 7-CKA binds with both favorable enthalpy and entropy. Previous analyses by ITC of ligand binding to isolated LBDs from AMPA receptors have shown that ligands stabilizing the closed-cleft conformations of the LBD differ from ligands stabilizing an extended cleft conformation with respect to their thermodynamic profile (Kasper et al., 2006; Martinez et al., 2014). On the basis of this, the observed differences in thermodynamic profiles may indicate that 7-CKA has a different binding mode than β-fluoro-DL-alanine, D-Ser, and glycine, and further suggest that 7-CKA may stabilize a distinctly different LBD conformation than the amino acid ligands.

Structural analysis of 7-CKA bound GluD2-LBD by X-ray crystallography – In order to determine the binding mode of 7-CKA to GluD2 and the molecular details underlying its different thermodynamic profile, we crystallized GluD2-LBD in complex with 7-CKA. The structure of the 7-CKA-bound GluD2-LBD was determined to 2.5 Å resolution and revealed that the complex crystallizes as a monomer with one GluD2 LBD protomer in the asymmetric unit of the crystal (Table 3). The electron density of 7-CKA in the ligand-binding site of the GluD2-LBD is well-defined and allowed unambiguous positioning of the ligand and identification of ligand contacts (Fig. 4). The structure showed one molecule of 7-CKA bound within the cleft formed by domains D1 and D2 of the clamshell-shaped LBD structure (Fig. 4A, B). Like D-Ser (Naur et al., 2007), 7-CKA is anchored to the LBD through a bidentate salt bridge formed between the carboxylate group of 7-CKA and the side chain guanidine group of Arg530 (Fig. 4B, C). In addition, one carboxylate oxygen atom of 7-CKA forms a hydrogen bond to the backbone nitrogen of Thr525. A hydrogen bond is also seen between the ring nitrogen atom of 7-
CKA and the backbone carbonyl of Ala523, suggesting that the ring nitrogen atom is protonated and that 7-CKA therefore binds in its keto-form. To further investigate this, we performed ab initio calculations of the two tautomeric states to determine which state is dominant in solution. The results showed that the keto-form had a 12.3 kcal/mol lower energy than the enol-form, supporting the proposed hydrogen bond between the ring NH group and the backbone carbonyl of Ala523 (Fig. 4C). The carbonyl oxygen atom of 7-CKA forms contacts to the backbone nitrogen of Ala686 and two water molecules. 7-CKA is surrounded by several hydrophobic residues of which the ligand forms optimal stacking with Tyr496 (Fig. 4C). In addition, two 7-CKA molecules were found to bind to surface residues of GluD2-LBD (see Supplemental Fig. 1). Compared to the previously reported structure of the GluD2-LBD in complex with D-Ser (Naur et al., 2007), there is a striking difference in the degree of cleft opening between domains D1 and D2 of the GluD2-LBD in the 7-CKA bound structure (Fig. 4D). Relative to the D-Ser induced conformation, the D1 and D2 domain opening of GluD2-LBD in complex with 7-CKA is 19.5 degrees more open. Thus, the 7-CKA induced GluD2-LBD conformation is closer to the apo conformation, which has a domain opening of 29.9 degrees relative to the D-Ser induced conformation.

Crystal structures of isolated LBDs from AMPA and NMDA receptor subunits have found that antagonists unambiguously stabilize LBD conformations with domain opening similar or close to the apo conformation (Pohlsgaard et al., 2011). By contrast, iGluR agonists induce substantial domain closure, which triggers subsequent conformational changes that lead to channel opening (Armstrong and Gouaux, 2000; Pohlsgaard et al., 2011). Comparison of the degree of domain closures in the GluD2-LBD for structures in the apo conformation and with bound 7-CKA or D-Ser suggests that 7-CKA binding at full-length GluD2 induces less
conformational changes relative to D-Ser, and raises the possibility that 7-CKA is a competitive antagonist at the D-Ser binding site. The GluD2 signaling mechanism has not yet been reconstituted in heterologous expression systems and it is at present not possible to directly examine whether ligands have agonist or antagonist activity. Direct ligand-activity at the wild-type GluD2 receptor can so far only be studied via effects on the constitutive current generated by GluD2LC mutant receptors. Considering the idea of 7-CKA as a potential antagonist of GluD2, it is perhaps surprising that 7-CKA produces similar effect as D-Ser at GluD2LC receptors; e.g. inactivation of the constitutive current although with lower efficacy (Fig. 2 and Table 1). However, it has been previously shown that reduction of GluD2LC-activity by D-Ser results from conformational changes at the LBD dimer interface (Hansen et al., 2009). Interestingly, conformational changes at the LBD dimer interface reflects desensitization of AMPA and kainate receptors (Armstrong et al., 2006; Daniels et al., 2013; Durr et al., 2014; Meyerson et al., 2014; Plested and Mayer, 2009; Schauder et al., 2013), and the extent of desensitization of AMPA receptors is correlated with the degree of domain closure (Jin and Gouaux, 2003). That is, ligands that induce full domain closure desensitize AMPA receptors to a higher extent than ligands that induce less closure. The present finding that 7-CKA inactivates GluD2LC currents less than D-Ser at saturating conditions (Fig. 2C) may suggest that inactivation of GluD2LC channel activity is linked to desensitization and is correlated to the degree of domain closure. However, an alternative mechanism could be that 7-CKA inhibits spontaneous GluD2LC channel opening by stabilizing the LBD in a more open conformation in contrast to D-Ser that inhibits by closing the LBD to promote desensitization. To distinguish between these two mechanism of GluD2LC channel inhibition by 7-CKA, we introduced an engineered disulfide bond at the interface between two GluD2-LBDs (Naur et al., 2007).
bond (GluD2<sup>LC</sup> P528+L789C) has been shown to be efficiently formed and to prevent the reduction of GluD2<sup>LC</sup>-activity by D-Ser resulting from conformational changes at the LBD dimer interface (i.e. desensitization) (Hansen et al., 2009). At GluD2<sup>LC</sup>, 10 mM D-Ser reduced spontaneous channel activity by 57 ± 3% compared to complete channel block by 100 µM 1-naphthyl acetyl spermine (NASP), whereas 1 mM 7-CKA inhibited GluD2<sup>LC</sup> by 27 ± 1% (N = 8) (Fig. 5). GluD2<sup>LC</sup> P528+L789C receptors with crosslinked dimer interface were inhibited 7 ± 1% by 10 mM D-Ser and 12 ± 1% by 1 mM 7-CKA (N = 6). Thus, crosslinking the GluD2<sup>LC</sup> dimer interface reduced D-Ser responses by 8.1-fold, whereas 7-CKA responses were modestly reduced by 2.3-fold (Fig. 5); hereby making 7-CKA more efficacious than D-Ser for reducing spontaneous channel activity. This result suggests that 7-CKA responses are mediated by conformational changes that are distinct from those induced by D-Ser binding, consistent with a mechanism where 7-CKA inhibits spontaneous GluD2<sup>LC</sup> channel opening by stabilizing the LBD in a more open conformation.
Discussion

The identification of a possible ligand-mediated signaling role of the GluD2 receptor through occupancy of the orthosteric binding site suggests that development of selective ligands for this site could be useful tools for studying the poorly understood cellular and molecular function of GluD2 (Hansen et al., 2009; Kakegawa et al., 2011; Orth et al., 2013; Williams et al., 2003; Wollmuth et al., 2000). Of particular importance is the development of a GluD2 selective antagonist, which could allow further investigation of the role of GluD2 in numerous processes. As a first step towards the development of new GluD2-selective ligands, we have exploited a focused library to identify ligands that modulate constitutively GluD2^{LC} channel activity. This allowed us to identify several new GluD2 ligands, including \textit{D}-Ser analogs as well structurally diverse compounds related to known iGluR antagonists. Among the latter group, we focused on the well-known NMDA receptor glycine-site competitive antagonist 7-CKA. The molecular mechanism of GluD2 signaling must include conformational changes initiated by \textit{D}-Ser binding to the LBD, which can be speculated to propagate to structural re-arrangement of the CTD. The CTD is linked to an array of intracellular interaction partners that may serve as effector molecules for regulation of processes within the post-synaptic signaling complex that contribute to synaptic plasticity. The crystallographic analysis of the GluD2-LBD shows that 7-CKA stabilizes the domain in a more open conformation relative to \textit{D}-Ser (Fig. 4). Furthermore, ITC and crosslinking experiments support that 7-CKA induces conformational changes that are distinct from those induced by \textit{D}-Ser. The observation that 7-CKA stabilizes the LBD in a conformation that is closer to the \textit{apo} conformation than to the \textit{D}-Ser bound conformation may indicate that 7-CKA binding in the intact GluD2 will not induce the receptor conformational changes that underlie \textit{D}-Ser signaling. In concert, these analyses may suggest that 7-CKA is a
competitive antagonist at the D-Ser binding site. Indeed, in their demonstration of D-Ser regulation of cerebellar LTD via GluD2, Kakegawa et al (2011) found that 7-CKA inhibits LTD induction independently of its activity at NMDARs. However, it should be noted that until the molecular mechanism of GluD2 signaling is identified, it is not possible to test directly if effects of ligand-binding to the orthosteric site are agonistic or antagonistic. Therefore, the suggestion that 7-CKA is a competitive antagonist at GluD2 is highly speculative.

Among the compounds for which EC\textsubscript{50} for GluD2\textsuperscript{LC} inactivation and K\textsubscript{d} for binding to the isolated GluD2-LBD was determined, 7-CKA and β-fluoro-DL-alanine were the most potent with EC\textsubscript{50} and K\textsubscript{d} in the lower micromolar range (Table 1 and 2). The results from our initial screening provide some initial insight into the structure-activity relationship (SAR) that might be of value for future efforts to improve potency. For example, agonist activity at iGluRs in general requires the LBD to adopt a conformation in which the D1 and D2 lobes are near-fully or fully closed around the ligand (Kumar and Mayer, 2013; Pohlsgaard et al., 2011). This may pose specific limits for the size of the agonist structure that depend on the volume of the ligand binding cavity. The structure of D-Ser bound to GluD2-LBD (Naur et al., 2007) shows the ligand binding pocket of GluD2 to be the smallest in volume among all iGluR LBD structures so far determined with D-Ser completely filling the cavity. The small volume may pose an important size constraint for future design efforts of new GluD2 agonists. Thus, creation of agonists with improved affinity by addition of larger functional groups to the scaffold of the endogenous agonist as has been found possible for analogs of L-glutamate at AMPA (Juknaite et al., 2012; Vogensen et al., 2011), NMDA (Clausen et al., 2008; Erreger et al., 2005; Hansen et al., 2013), and kainate (Juknaite et al., 2012; Zhou et al., 1997) receptors may prove difficult for GluD2. This is reflected in the present ligand screen where the only D-Ser analogs that preserve activity...
are those in which the core functional groups are replaced with functionalities of similar size (Fig. 1 and Supplemental Table S1). In particular, all substitutions at the \( \alpha \) - and \( \beta \)-carbons of D-Ser lead to loss-of-activity (Supplemental Table S1). Furthermore, replacement of the \( \beta \)-hydroxyl with larger polar substituents rendered the ligand inactive (Supplemental Table S1). The structure of GluD2-LBD in complex with D-Ser (Naur et al., 2007) shows the hydroxyl group to form a direct interaction with the binding pocket in the form of a hydrogen bond to the hydroxyl-group on Tyr543, and the importance of this interaction for compound potency may be illustrated from the decreased \( EC_{50} \) observed for D-Ala and 1-aminocyclopropane carboxylic acid (ACPC), in which the methyl hydroxyl side chain of D-Ser is removed or replaced by non-polar cyclopropane ring (Fig. 2 and Table 1).

Several compounds containing the quinoline scaffold of 7-CKA were also tested (Supplemental Table S4), allowing some information regarding the 7-CKA pharmacophore to be extracted (Fig. 6). Compound 87 differ from 7-CKA only by the absence of a chlorine atom at the 7-position, and induced 5% inactivation when evaluated at a concentration of 1 mM compared to the 59% inactivation produced by a similar concentration of 7-CKA (Fig. 6), demonstrating a key role of the substituent at the 7-position of the quinoline ring in defining ligand activity. The 7-CKA structure shows the chlorine to be located in a sub-pocket lined by polar side chain moieties of Phe563, Asp742 and Tyr770. Future introduction of other polar substituents with hydrogen bond formation properties may be of interest at this position. Interestingly, the compounds 78 and 86 also lack chlorine at the 7-position, but have a hydroxyl substituent at the 8-positions. Comparison of the activities of these analogs with that of compound 87 shows an interesting pattern with regards to hydroxyl substituent in the 8-position and ketone in the 4-position: Hydroxyl in the 8-position decreases activity when the 4-position
contains a ketone (compare compound 87 with compound 86; Fig. 6), but increases activity when the 4-position is unsubstituted. The GluD2-LBD structure with 7-CKA shows the 4-position ketone to form a hydrogen bond with the backbone nitrogen of Ala686 (Fig. 4C). Ala686 together with Ala523 and Thr525/Arg530 constitute a triangular set of interaction points for the 7-CKA molecule (Fig. 4C). Unlocking this binding mode by removing the 4-position ketone may allow different positioning of the planar quinoline scaffold in the pocket to allow polar substituents in the 8-position to form direct interactions with the binding pocket. Finally, an interesting observation is that compound 76 has activity in the range of 7-CKA (Fig. 6). Compound 76 differs from compound 87 (5% inactivation) only by having an ethoxy substituent instead of ketone in the 4-position. The ethyl moiety to the 4-position oxygen may reach into a hydrophobic sub-pocket lined by Trp741 (Fig. 6B), which suggest further exploration of alkoxy substituents in the 4-position to be warranted for improvement of potency.

In summary, the present identification and characterization of new ligands for the GluD2 receptor constitute a first step toward development of GluD2-selective ligands that could be used as pharmacological tools to explore the role of GluD2 receptors in the CNS. However, further experimentation aimed at providing a more detailed picture of ligand-binding effects on GluD2 receptor function is required. Such studies might focus on understanding the structural changes that is induced by the binding of different ligands in full-length GluD2, or explore functional effects of new disease-associated human mutations that may be identified in GluD2 (Yuan et al., 2015).
Acknowledgements

We thank the staff at MAX-lab, Lund, Sweden for help during data collection.
Authorship contributions

Participated in research design: Kristensen, Hansen, Kastrup, Traynelis

Conducted experiments: Kristensen, Hansen, Naur, Olsen, Levasseur, Dravid, Kvist, Yi.

Contributed new reagents or analytical tools: Pøhlsgaard, Clausen, Gajhede.

Performed data analysis: Kristensen, Hansen, Yi, Naur, Olsen, Levasseur, Dravid, Kastrup, Traynelis.

Wrote or contributed to the writing of the manuscript: Kristensen, Hansen, Olsen, Naur, Clausen Gajhede, Kastrup, Traynelis.
References


Footnotes

This work was supported by National Institute of Mental Health Grant [R21-MH062204] to SFT, National Institute of General Medicine grant [P20-GM103546] to SFT, the National Alliance for Research on Schizophrenia and Depression to SFT, Alfred Benzon Foundation grants to ASK. and KBH, the Danish Medical Research Council grants to ASK, JSK, LO, MG, and P.N.A., the GluTarget Programme of Excellence at the University of Copenhagen grant to TK, JSK, and ASK, the Danish Ministry of Science, Innovation and Higher Education’s EliteForsk Programme travel grant to TK, Lundbeck Foundation grant to JSK, LO, MG; JP, PNA, Carlsberg Foundation grant to JSK, LO, and MG, DANSCATT to JSK, LO, MG, and PNA, and a University of Copenhagen Drug Research Academy stipend to PNA.
Legends for Figures

Figure 1. Identification of novel GluD2 ligands. A) Representative current traces illustrate the recording protocol used for compound screening at GluD2^{LC} receptors expressed in *Xenopus* oocytes. Compounds were screened at a concentration of 0.1 or 1 mM depending on solubility and availability. Numbers refer to compounds in the screening library (see Supplementary Table S1 to S4). B and C). Chemical structures and summary of activity of compounds identified to have more than 50% activity of D-Ser (1 mM) when applied at a concentration of 1 mM or more than 20% activity when applied at a concentration of 100 µM: D-alanine (D-Ala), β-fluoro-DL-alanine (β-fluoro-Ala), 1-aminocyclopropane carboxylic acid (ACPC), (R)-2-(methylamino)succinic acid (N-methyl-D-aspartic acid; NMDA), 7-chloro-4-oxo-1H-quinoline-2-carboxylic acid (7-CKA), 5-bromo-7-(trifluoromethyl)-1,4-dihydroquinazoline-2,3-dione (BMTX), (2S,4R)-5,7-dichloro-4-(3-phenylureido)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid (L-689,560), 2-phenyl-1H-benzo[d]imidazole-5-sulfonic acid (PBSA), ethyl 4-ethoxy-2-oxo-1,2-dihydro-3-quinolinecarboxylate (ODQC).

Figure 2. Concentration-effect relationship for inhibition of GluD2^{LC} currents by selected compounds. A and B) Representative current traces for D-Ser (A) and 7-CKA (B) illustrate the recording protocol used for determination of compound potency for inhibition of constitutively active GluD2^{LC} receptors expressed in *Xenopus* oocytes. C) Average composite concentration-response curves. Error bars are S.E.M. and are shown when larger than symbol size. The current responses are normalized to the maximal response produced by D-Ser.
Figure 3. Isothermal titration calorimetry studies on GluD2-LBD. A plot of energy transfer rate as a function of molar ratio (upper panels) and integrated data after subtraction of the heat of dilution (lower panels) of β-fluoro-DL-alanine (A) and 7-CKA (B) are shown. The solid lines represent the best-fit curves to the data, using a one-site binding model (Materials and Methods).

Figure 4. X-ray structure of GluD2-LBD in complex with 7-CKA. A) Schematic cartoon illustrating the modular architecture of a GluD2 receptor subunit that contains an N-terminal domain (NTD) and a bilobed LBD with D1 and D2 subdomains that are connected to a transmembrane domain (TMD) consisting of three membrane-spanning segments (M1, M3 and M4) and a short membrane re-entrant segment (M2) and a C-terminal domain (CTD). B) Ribbon representation of the crystal structure of the isolated GluD2-LBD with 7-CKA bound. The D1 and D2 subdomains are highlighted in orange (D1) and blue (D2). The molecular structure of 7-CKA (shown as stick representation) bound in the cleft between D1 and D2 subdomains is shown as an expanded inset. The binding pocket surface is shown as transparent contour and key interacting side chains are shown as sticks. The GluD2 amino acid numbering is started with the initiating methionine in the full-length GluD2 sequence that includes the signal peptide. C) Two-dimensional representation of the binding pocket generated using LigPlot (Wallace et al., 1995), showing contacts to binding site residues. D) Domain opening of the GluD2-LBD in the apo (left), 7-CKA (center) and D-Ser (right) bound states. The domain openings are relative to that induced by D-Ser.

Figure 5. Effects of crosslinking the LBD dimer interface in GluD2LC on D-Ser and 7-CKA responses. A) Representative current traces for responses to 10 mM D-Ser, 1 mM 7-CKA, and
100 µM NASP on GluD2^{LC} and GluD2^{LC} P528C+L789C expressed in *Xenopus* oocytes. The P528C+L789C mutations crosslink the LBD dimer interface in GluD2^{LC} by the formation of a disulfide bond. (B) Bar graph of the mean responses to D-Ser and 7-CKA as percentage of complete inhibition by the channel blocker NASP. Error bars are S.E.M. and the data are from 6-8 oocytes.

**Figure 6.** 7-CKA structure-activity relationship. Shown is the quinoline scaffold of 7-CKA (A) with ring positions numbered from 1 to 8 along with graphical summary (B) of the activity of analogs with various combinations of ring substituents (R₁ to R₈). Compound numbers refer to the listing in Supplemental Table S4.
### Table 1. Compound potency at GluD2<sup>LC</sup>

<table>
<thead>
<tr>
<th>Compound&lt;sup&gt;a&lt;/sup&gt;</th>
<th>EC&lt;sub&gt;50&lt;/sub&gt; (µM)</th>
<th>Hill slope</th>
<th>Efficacy (% D-Ser)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D-Ser</td>
<td>250 [214 – 293]</td>
<td>1.1 [0.9 – 1.3]</td>
<td>100</td>
</tr>
<tr>
<td>7-CKA</td>
<td>312 [236 - 413]</td>
<td>1.1 [0.8 – 1.4]</td>
<td>53 [47 – 59]</td>
</tr>
<tr>
<td>ACPC</td>
<td>&gt;500</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>NMDA</td>
<td>&gt;1000</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>PBSA</td>
<td>317 [225 - 448]</td>
<td>1.0 [0.7 – 1.3]</td>
<td>59 [55 – 63]</td>
</tr>
<tr>
<td>D-Ala</td>
<td>805 [686 to 945]</td>
<td>1.0 [0.9 – 1.2]</td>
<td>98 [92 – 103]</td>
</tr>
</tbody>
</table>

<sup>a</sup> See Figure 1 legend for full compound names.

<sup>b</sup> EC<sub>50</sub> values were determined by the nonlinear fitting of concentration-inhibition data collected from 6–10 oocytes (see Materials and Methods). Numbers in brackets denote the 95% confidence interval for the fitted EC<sub>50</sub>.
Table 2. Thermodynamic characteristics of ligand binding to the isolated GluD2-LBD determined by ITC

<table>
<thead>
<tr>
<th>Compound</th>
<th>$K_d$ (µM)</th>
<th>$\Delta G$ (kcal/mol)</th>
<th>$\Delta H$ (kcal/mol)</th>
<th>$-T\Delta S$ (kcal/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycine$^a$</td>
<td>2754</td>
<td>-3</td>
<td>2</td>
<td>-5</td>
</tr>
<tr>
<td>D-Ser$^a$</td>
<td>925</td>
<td>-4</td>
<td>3</td>
<td>-7</td>
</tr>
<tr>
<td>D-Ala</td>
<td>1919</td>
<td>-4</td>
<td>2</td>
<td>-5</td>
</tr>
<tr>
<td>$\beta$-Fluoro-DL-alanine</td>
<td>1519</td>
<td>-4</td>
<td>4</td>
<td>-7</td>
</tr>
<tr>
<td>7-CKA</td>
<td>80</td>
<td>-6</td>
<td>-2</td>
<td>-4</td>
</tr>
</tbody>
</table>

$^a$ from Naur et al. (2007).
Table 3. Data collection and refinement statistics for GluD2-LBD in complex with 7-CKA

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Space group</strong></td>
<td>$P4_{3}2_{1}2$</td>
</tr>
<tr>
<td><strong>Unit cell (Å)</strong></td>
<td>$a = b = 70.2, c = 134.5$</td>
</tr>
<tr>
<td><strong>No. per a.u.$^a$</strong></td>
<td>1</td>
</tr>
<tr>
<td><strong>Crystal mosaicity (deg.)</strong></td>
<td>0.78-0.87</td>
</tr>
<tr>
<td><strong>Resolution (Å)</strong></td>
<td>30-2.5</td>
</tr>
<tr>
<td><strong>Total observations</strong></td>
<td>62324</td>
</tr>
<tr>
<td><strong>Unique observations</strong></td>
<td>12222</td>
</tr>
<tr>
<td><strong>$I/\sigma(I)^b$</strong></td>
<td>13.4 (2.8)</td>
</tr>
<tr>
<td><strong>Completeness (%)$^b$</strong></td>
<td>99.6 (100)</td>
</tr>
<tr>
<td><strong>$R_{merge} (%)^{b,c}$</strong></td>
<td>7.2 (51.9)</td>
</tr>
<tr>
<td><strong>$R_{work} (%)^d$</strong></td>
<td>19.2</td>
</tr>
<tr>
<td><strong>$R_{free} (%)^e$</strong></td>
<td>23.9</td>
</tr>
<tr>
<td><strong>No. of GluD2 residues/7-</strong></td>
<td>258/3/1/1/24</td>
</tr>
<tr>
<td><strong>CKA/chloride/glycerol/water</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Average B-values protein/7-</strong></td>
<td>53/40/71/57/44</td>
</tr>
<tr>
<td><strong>CKA/chloride/glycerol/water (Å$^2$)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Rms bond lengths/angles (Å/deg.)</strong></td>
<td>0.003/0.7</td>
</tr>
<tr>
<td><strong>Ramachandran favored/outliers (%)$^f$</strong></td>
<td>98.0/0.4(Asp504)</td>
</tr>
</tbody>
</table>

$^a$ Number of protein molecules per asymmetric unit (a.u).

$^b$ Values in parentheses are statistics for the highest resolution bin (2.66-2.50 Å).
$R_{\text{merge}} = \frac{\sum_{hkl} |I_{hkl} - <I_{hkl}>|}{\sum_{hkl} I_{hkl}},$ where $I_{hkl}$ is the measured intensity of the reflections with indices $hkl$.

$R_{\text{work}} = \frac{\sum_{hkl} (|F_{o,hkl}| - |F_{c,hkl}|)}{|F_{o,hkl}|},$ where $|F_{o,hkl}|$ and $|F_{c,hkl}|$ are the observed and calculated structure factor amplitudes.

Five percent of the reflections in the data set were set aside for calculation of the $R_{\text{free}}$ value.

The Ramachandran plot was calculated according to MolProbity (Davis et al., 2007) implemented in Phenix.
Figure 5

**A**

- GluD2<sup>LC</sup>
- D-Ser
- 7-CKA
- NASP

- GluD2<sup>LC</sup> P528C+L789C
- D-Ser
- 7-CKA

**B**

Graph showing % of NASP with bars for D-Ser and 7-CKA for GluD2<sup>LC</sup> P528C+L789C.